Art. -Nr.: HY-76201

Dexrazoxane hydrochloride

(Synonyms: ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride)

19 Cited Publications

Kundenbewertung

Based on 19 publication(s) in Google Scholar

Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 149003-01-0
Formel: C₁₁H₁₈Cl₂N₄O₄
Molecular Weight:341.19

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Dexrazoxane hydrochloride Chemical Structure

CAS. Nr.: 149003-01-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (19)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

As a derivative of EDTA, dexrazoxane chelates iron, thus reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. This agent is used to protect the heart against the cardiotoxic side effects of anthracyclines, such as doxorubicin. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.

In Vitro

Dexrazoxane (0-500 μM; 0-24 h) induces DNA breaks, ATF3 accumulation, DNA damage response and apoptosis in human fibrosarcoma cell line^[1].
Dexrazoxane hydrochloride protects ovarian cells from DXR-induced DNA damage (neutral comet assay)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Topoisomerase IIα-expressing HTETOP cells (HTETOP cells were derived from the human fibrosarcoma cell line HT1080 through the deletion of both endogenous topoisomerase IIα alleles and the insertion of a tetracycline-repressible topoisomerase IIα transgene)
Concentration:

100 μM
Incubation Time:

4 h
Result:

Increased the phosphorylation level of Chk1, Chk2, ATR, and ATM.

Western Blot Analysis^[1]

Cell Line:

HTETOP cells
Concentration:

0, 10, 100 and 500 μM
Incubation Time:

0, 1, 4, 8 and 24 h
Result:

Increased AFT3 protein levels in a concentration-dependent and incubation time-dependent manner.

Western Blot Analysis^[1]

Cell Line:

Topoisomerase IIα-expressing HTETOP cells
Concentration:

100 μM
Incubation Time:

24 h
Result:

Increased the expression level of P53.

In Vivo

Dexrazoxane hydrochloride (20 mg/kg, intraperitoneal injection, single dose) reduces acute ovarian toxicity induced by DXR (HY-121259) in mice, improving long-term fertility^[2].
Dexrazoxane hydrochloride (0-120 mg/kg, intravenous injection, once a week for 13 weeks) dose-dependently reduces DOX-induced heart toxicity in rats, mice, and dogs, but the efficacy decreases at higher doses of DOX^[3].
Dexrazoxane hydrochloride (1.5-15 mg/kg, intraperitoneal injection, single dose) improves motor dysfunction in mice, protects dopaminergic neurons from neurotoxin-induced SNc degeneration, along with reduced activation of glial cells, and inhibits oxidative stress and endoplasmic reticulum stress^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CD-1 mice induced by DXR^[2]
Dosage:

20 mg/kg, single dose
Administration:

Intraperitoneal injection (i.p.)
Result:

Reduced the degree of DNA double-strand breaks, reduced the activation of γ-h2fax, reduced follicular cell death, reduced the infertility index, and improved fertility.

Animal Model:

ICR Swiss mouse, Sprague Dawley rat, Beagle dog induce by DOX^[3]
Dosage:

0, 10, 20, 40, 80, 120 mg/kg (10 times DOX in 7 weeks); 4, 8, 16 mg/kg (once a week DOX, 13 weeks); 2, 6, 16 mg/kg (once a week DOX, 13 weeks)
Administration:

Intravenous injection (i.v.)
Result:

Deduced MTS in mice at different dose ratios, but the effect was less effective for higher doses of DOX. In rats, MTS was reduced in both sexes, but cardiac damage was still evident in male rats that received the highest dose of DOX. MTS decreased significantly in both sexes but cardiac lesions were still observed in dogs in all treatment groups.

Animal Model:

Rat induced by 6-OHDA (HY-B1081A)^[4]
Dosage:

1.5, 5, 10, 15 mg/kg; single dose
Administration:

Intraperitoneal injection (i.p.)
Result:

Improved contralateral rotation behavior, inhibited the activation of microglia in the SNc, reversed the ratio of the injured side to the intact side in the number of TH+ immunoreactive neurons, inhibited TNF-α and IL-1β content, abolished MDA formation, and reduced the changes in GSHPX and SOD.

Chemical Information

CAS. Nr. 149003-01-0
Appearance Solid
Molecular Weight 341.19
Formel C₁₁H₁₈Cl₂N₄O₄
Color White to off-white
SMILES

C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O.[H]Cl.[H]Cl
Synonyms

ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (19)

All Bio/Physico-chemical AssayFlow CytometryCell Imaging/StainingRT-PCRIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Med

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. [Abstract]

2016 May;22(5):547-56. PMID: 27089514
Adv Sci (Weinh)

The Imbalance of p53-Park7 Signaling Axis Induces Iron Homeostasis Dysfunction in Doxorubicin-Challenged Cardiomyocytes. [Abstract]

2023 May;10(15):e2206007. PMID: 36967569

Dexrazoxane hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in contractile speed in NMCMs.

Dexrazoxane hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in cell viability in NMCMs.

Dexrazoxane hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) inhibited DOX-induced iron accumulation and ROS and restored mitochondrial membrane potential in NMCMs.

Dexrazoxane hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (1 µM; 24 h) reversed Ptgs2 mRNA expression in NMCMs.

Dexrazoxane hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]

Dexrazoxane (DXZ) (20 mg/kg; i.p.; weekly for 4 weeks) reversed the DOX-induced decrease in body weight and the ratio of heart weight to tibia length (HW/TL) of chronic DoIC (doxorubicin (DOX)-induced cardiotoxicity) mice.
Nano Res

2023 Apr 18.
J Pharm Anal

2026 Mar 10.
Phytomedicine

Quercetin ameliorates doxorubicin-induced atrial fibrillation via EGFR-mediated restoration of autophagic flux. [Abstract]

2025 Oct 3:148:157357. PMID: 41056856
Phytomedicine

20-Deoxyingenol attenuated doxorubicin-induced cardiotoxicity by promoting autolysosome degradation through the UCHL3-TFEB pathway. [Abstract]

2025 Nov:147:157220. PMID: 40916238
Phytomedicine

Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway. [Abstract]

2023 Aug:117:154922. PMID: 37321078
Free Radic Biol Med

Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. [Abstract]

2024 Dec 9:227:296-311. PMID: 39653130
Free Radic Biol Med

Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. [Abstract]

2020 Nov 20;160:303-318. PMID: 32846217
Br J Pharmacol

Targeting FDX1 by trilobatin to inhibit cuproptosis in doxorubicin-induced cardiotoxicity. [Abstract]

2025 Jun;182(11):2409-2425. PMID: 39933533
Biomed Pharmacother

ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. [Abstract]

2022 Sep:153:113280. PMID: 35724508
Eur J Med Chem

Praeruptorin A screened by a ferrous ion probe inhibited DMT1 and ferroptosis to attenuate Doxorubicin-induced cardiomyopathy. [Abstract]

2024 Nov 26:283:117108. PMID: 39615370
Biochem Pharmacol

Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway. [Abstract]

2024 Jun:224:116247. PMID: 38697311
J Ethnopharmacol

Huanglian-ejiao decoction ameliorates doxorubicin-induced cardiomyocyte apoptosis and autophagic flux dysregulation by up-regulating ubiquilin1. [Abstract]

2025 Oct 14:120751. PMID: 41101550
J Cell Mol Med

Downregulation of Alox5 Inhibits Ferroptosis to Improve Doxorubicin-Induced Cardiotoxicity via the P53/SLC7A11 Pathway. [Abstract]

2025 Jun;29(11):e70641. PMID: 40485049
Environ Toxicol Pharmacol

Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. [Abstract]

2023 Oct:103:104261. PMID: 37689219
Cardiovasc Toxicol

Marein Alleviates Doxorubicin-Induced Cardiotoxicity through FAK/AKT Pathway Modulation while Potentiating its Anticancer Activity. [Abstract]

2024 Aug;24(8):818-835. PMID: 38896162
Mol Med Rep

Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress. [Abstract]

2024 May;29(5):84. PMID: 38516760
Biochem Biophys Res Commun

The m6A modification reader protein IGF2BP2 regulates ferroptosis in nasopharyngeal carcinoma cells by stabilizing CP expression via an m6A-dependent mechanism. [Abstract]

2025 Sep 8:778:152417. PMID: 40743989

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (146.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 20 mg/mL (58.62 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9309 mL

14.6546 mL

29.3092 mL

5 mM

0.5862 mL

2.9309 mL

5.8618 mL

10 mM

0.2931 mL

1.4655 mL

2.9309 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 130 mg/mL (381.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shiwei Deng, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172(9):2246-57. [Content Brief]

[2]. Jenna Kropp, et al. Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice. PLoS One. 2015 Nov 6;10(11):e0142588. [Content Brief]

[3]. A R Imondiv, et al. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res. 1996 Sep 15;56(18):4200-4. [Content Brief]

[4]. Meng Mei, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1:160:107758. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.9309 mL	14.6546 mL	29.3092 mL	73.2730 mL
	5 mM	0.5862 mL	2.9309 mL	5.8618 mL	14.6546 mL
	10 mM	0.2931 mL	1.4655 mL	2.9309 mL	7.3273 mL
	15 mM	0.1954 mL	0.9770 mL	1.9539 mL	4.8849 mL
	20 mM	0.1465 mL	0.7327 mL	1.4655 mL	3.6636 mL
	25 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9309 mL
	30 mM	0.0977 mL	0.4885 mL	0.9770 mL	2.4424 mL
	40 mM	0.0733 mL	0.3664 mL	0.7327 mL	1.8318 mL
	50 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
DMSO	60 mM	0.0488 mL	0.2442 mL	0.4885 mL	1.2212 mL
	80 mM	0.0366 mL	0.1832 mL	0.3664 mL	0.9159 mL
	100 mM	0.0293 mL	0.1465 mL	0.2931 mL	0.7327 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Dexrazoxane hydrochloride

19 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dexrazoxane hydrochloride

Apoptosis Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Endoplasmic Reticulum Stress Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Dexrazoxane hydrochloride

Biologische Aktivität

Chemical Information

Publications (19)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dexrazoxane hydrochloride Related Classifications

Art. -Nr.: HY-76201